Toyota Teams Up with Microsoft and 4 Hot Stocks Seeing Action
Zillow Inc (NASDAQ:Z) share weakness is being blamed on a letter that was posted on the SEC’s website, with a date of August 30, to the Zillow’s CEO Spencer Rascoff. The letter shows the SEC questioning the reasons why the company would avoid revealing the percentage rise in the average price paid for Premier Agent subscriptions.
Toyota Motor Corp. (NYSE:TM) has chosen Microsoft’s technology platforms for the development of its communications and collaboration infrastructure to be used by the Toyota companies globally. Toyota along with additional affiliates in North America started the deployment of Microsoft Office 365-dedicated cloud services as its exclusive environment in June 2012. Toyota is to be leveraging a hybrid model in Japan and along with other overseas locations, with on-premises editions of Microsoft Exchange, Microsoft SharePoint, Microsoft Lync, and Windows Server. Microsoft intends to assist Toyota in offering these services to over 200,000 employees worldwide during the following two years. The goal of this move is to improve support mobile devices, lower costs, and make collaboration better between employees via innovative enterprise social networking, conferencing, messaging, and information-sharing tools.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Rosetta Genomics, Ltd. (NASDAQ:ROSG) along with privately held Precision Therapeutics announced its commercial release of the miRview mets^2 assay in the U.S. oncology market. miRview mets^2 is a diagnostic tool used by clinicians to evaluate of the Cancer of Unknown/Uncertain Primary patients.
Celgene Corporation (NASDAQ:CELG): Celgene International Sarl, which is a subsidiary of Celgene Corporation, announced the results of its phase III, randomized, international study of ABRAXANE in patients without chemotherapy diagnosed with metastatic melanoma. The primary endpoint was reached in the study with patients that recieved ABRAXANE showing statistically significant improvements regarding progression-free survival versus patients being treated with dacarbazine chemotherapy. The safety profile of ABRAXANE observed in the CA033 study continues to be consistent with other ABRAXANE pivotal clinical trials. This study data is scheduled to be presented at the Society for Melanoma Research Congress 2012 in Los Angeles in November. Because of these results, the future regulatory and clinical strategies are in the process of review.
Microsoft Corporation (NASDAQ:MSFT) gave MSN service some more touchups on Monday, attempting to make it look and feel much like the most recent versions of its other online properties. MSN seems to be attempting to resemble the look and feel of a Windows 8 app, as it scrolls to the right instead of down. Users will likely either love or hate this new feature.
Don’t Miss: Are Ford and GM Getting Friendly?